Iterum Therapeutics Business Summary

Iterum Therapeutics plc is a commercial-stage biopharmaceutical company that generates revenue primarily through the domestic sale of its lead product, ORLYNVAH™ (sulopenem etzadroxil and probenecid), which received FDA approval in late 2024 for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited alternative options. The company operates within a single business segment focused on the development and commercialization of differentiated anti-infectives designed to combat multi-drug resistant (MDR) pathogens. Iterum utilizes a capital-efficient commercialization model, partnering with EVERSANA for U.S. market operations and targeting high-volume prescribers to capture a niche in the outpatient infectious disease market. Its primary direct competitors include Spero Therapeutics, Scynexis, and Utility Therapeutics, the latter of which markets the competing uUTI antibiotic Pivya. Iterum distinguishes itself as a pure-play commercial entity offering the first and only oral penem approved in the United States, positioning it as a critical alternative to failing fluoroquinolone and beta-lactam therapies. The company was founded in 2015 by a leadership team with a deep pedigree in anti-infective development, including CEO Corey Fishman and CFO Judith Matthews, both of whom previously held executive roles at Durata Therapeutics where they oversaw the successful launch of Dalvance and the company's subsequent sale to Actavis. The executive team is further bolstered by Chief Commercial Officer Christine Coyne, a seasoned industry veteran who joined in 2025 to lead the ORLYNVAH™ launch. The board is chaired by David G. Kelly, a former executive at Horizon Therapeutics, and includes notable members such as Dr. Michael Dunne, the former Chief Medical Officer of the Gates Medical Research Institute and a key architect of Pfizer’s infectious disease portfolio. Iterum has historically attracted high-profile institutional backing from investors such as Sarissa Capital Management, Frazier Healthcare Partners, and Sofinnova Investments, reflecting strong industry confidence in its clinical and regulatory strategy.